Advertisement

More articles from Erratum

You have access
Correction to “Protective Effect of Anwulignan on Gastric Injury Induced by Indomethacin in Mice”
Journal of Pharmacology and Experimental Therapeutics January 2023, 384 (1) 204; DOI: https://doi.org/10.1124/jpet.121.001055err
You have access
Correction to “Interactive Effects of µ-Opioid and Adrenergic-α₂ Receptor Agonists in Rats: Pharmacological Investigation of the Primary Kratom Alkaloid Mitragynine and Its Metabolite 7-Hydroxymitragynine”
Journal of Pharmacology and Experimental Therapeutics February 2023, 384 (2) 326; DOI: https://doi.org/10.1124/jpet.122.001192err
You have access
Correction to “Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for μ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats”
Journal of Pharmacology and Experimental Therapeutics December 2022, 383 (3) 250; DOI: https://doi.org/10.1124/jpet.120.000189err
You have access
Correction to “Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases”
Journal of Pharmacology and Experimental Therapeutics December 2022, 383 (3) 251; DOI: https://doi.org/10.1124/jpet.121.001069err
You have access
Correction to “The Skeletal Muscle Relaxer Cyclobenzaprine Is a Potent Non-Competitive Antagonist of Histamine H1 Receptors”
Journal of Pharmacology and Experimental Therapeutics June 2022, 381 (3) 274; DOI: https://doi.org/10.1124/jpet.121.000998err
You have access
Correction to “Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity”
Journal of Pharmacology and Experimental Therapeutics April 2022, 381 (1) 67; DOI: https://doi.org/10.1124/jpet.121.000821err
You have access
Correction to “A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor ɣ with Excellent Effect on Insulin Resistance and Type 2 Diabetes”
Journal of Pharmacology and Experimental Therapeutics January 2022, 380 (1) 90-91; DOI: https://doi.org/10.1124/jpet.115.223107err
You have access
Correction to “Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II – Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertensin”
Journal of Pharmacology and Experimental Therapeutics September 2021, 378 (3) 322; DOI: https://doi.org/10.1124/jpet.121.000525err
You have access
Correction to “Inhibition of Glucose-6-Phosphate Dehydrogenase Activity Attenuates Right Ventricle Pressure and Hypertrophy Elicited by VEGFR Inhibitor + Hypoxia”
Journal of Pharmacology and Experimental Therapeutics August 2021, 378 (2) 69; DOI: https://doi.org/10.1124/jpet.120.000166err
You have access
Correction to “Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome”
Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 368; DOI: https://doi.org/10.1124/jpet.119.262238err

Pages